KO-2806 Monotherapy and Combination Therapies in Advanced Solid Tumors
Status:
Recruiting
Trial end date:
2027-04-01
Target enrollment:
Participant gender:
Summary
This first-in-human (FIH) dose-escalation and dose-validation/expansion study will assess
KO-2806, a farnesyl transferase inhibitor (FTI), as a monotherapy and in combination, in
adult patients with advanced solid tumors.